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Abstract
To clarify the role of Angiotensin II (Ang II) in the sensory system and especially in the trigeminal
ganglia, we studied the expression of angiotensinogen (Ang-N)-, renin-, angiotensin converting
enzyme (ACE)- and cathepsin D-mRNA, and the presence of Ang II and substance P in the rat and
human trigeminal ganglia. The rat trigeminal ganglia expressed substantial amounts of Ang-N- and
ACE mRNA as determined by quantitative real time PCR. Renin mRNA was untraceable in rat
samples. Cathepsin D was detected in the rat trigeminal ganglia indicating the possibility of existence
of pathways alternative to renin for Ang I formation. In situ hybridization in rat trigeminal ganglia
revealed expression of Ang-N mRNA in the cytoplasm of numerous neurons. By using
immunocytochemistry, a number of neurons and their processes in both the rat and human trigeminal
ganglia were stained for Ang II. Post in situ hybridization immunocytochemistry reveals that in the
rat trigeminal ganglia some, but not all Ang-N mRNA-positive neurons marked for Ang II. In some
neurons Substance P was found colocalized with Ang II. Angiotensins from rat trigeminal ganglia
were quantitated by radioimmunoassay with and without prior separation by high performance liquid
chromatography. Immunoreactive angiotensin II (ir-Ang II) was consistently present and the sum of
true Ang II (1-8) octapeptide and its specifically measured metabolites were found to account for it.
Radioimmunological and immunocytochemical evidence of ir-Ang II in neuronal tissue is compatible
with Ang II as a neurotransmitter. In conclusion, these results suggest that Ang II could be produced
locally in the neurons of rat trigeminal ganglia. The localization and colocalization of neuronal Ang
II with Substance P in the trigeminal ganglia neurons may be the basis for a participation and function
of Ang II in the regulation of nociception and migraine pathology.
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1. Introduction
The trigeminal ganglion, a cranial analog of the dorsal root ganglia in the peripheral nervous
system, is the site of primary sensory neurons involved in the regulation of nociception,
thermoreception, proprioception and mechanoreception in the facial skin, eye, nasal and oral
cavities, teeth and periodontal tissue and vibrissae [30] and provides sensory afferents to the
cerebral blood vessels [15]. The trigeminovascular system plays an essential role in the
pathophysiology of migraine [6,18], in the cerebrovascular vasospasm occurring after
subarachnoid hemorrhage [23] and in chronic pain and inflammatory syndromes [13].
A multitude of transmitters and neuromodulators have been described in the trigeminal
ganglion and its primary afferent neurons exhibit pathway-specific patterns of neurochemical
expression and transmitter colocalization [30]. However, the presence and specific localization
of renin-angiotensin system (RAS) components and role of angiotensin II (Ang II) has not been
studied, in spite of the association of Ang II with central and peripheral sensory systems [4,5,
52,54] and its proposed role in the regulation of pain [22,43], cerebrovascular inflammation
[2,57] and migraine [49,51].
Formation of circulating and local Ang II is mediated through activation of the RAS. The RAS
includes a precursor, angiotensinogen (Ang-N) cleaved by the enzyme renin to produce the
decapeptide angiotensin I (Ang I). In turn, Ang I is cleaved by angiotensin converting enzyme
(ACE) to generate the active RAS principle, the octapeptide Ang II [11].
Existence of an endogenous angiotensinergic system in the neurons of rat and human
sympathetic coeliac ganglia innervating mesenteric resistance arteries has been reported
recently [37]. Here we address the issue of the possible formation and localization of Ang II
in the trigeminal ganglion by determination of Ang-N-, Renin-, ACE- and Cathepsin D-mRNA
by qRT-PCR in rat trigeminal ganglia, by using in situ hybridization of the Ang II precursor
Ang-N mRNA in rat trigeminal ganglia and the expression of Ang II by immunocytochemistry
in rat as well as in human trigeminal ganglia. Several studies substantiated the role of substance
P in the regulation of sensory transmission in the trigeminal ganglion [17,24,25,30] and the
involvement of Ang II in the regulation of Substance P release [14,28]. Hence we attempted
to determine the possible formation and localization of Ang II in the neurons of trigeminal
ganglion and colocalization with Substance P in the same neurons.
2. Methods
2.1. Rat and human trigeminal ganglia
We purchased 8-week-old, male Wistar Kyoto (WKY) rats (approximately 200 g body weight)
from the Central Animal Facilities of the University of Bern. Adequate measures were taken
to minimize pain or discomfort, in accordance with the European Communities Council
Directive of 24 November 1986 (86/609/EEC) and in accordance with Animal Protocols
approved by the Animal Care and Use Committee, NIMH, NIH, USA. Rats were anaesthetized
intraperitoneally with 100 mg/kg thiopentane sodium and were perfused transcardially with
150 ml Ringer solution containing 1000 U heparin at 37 °C followed by 300 ml 2% freshly
prepared formaldehyde at 4 °C. Trigeminal ganglia were carefully dissected and incubated by
immersion fixation in 2% formaldehyde for 28 h at 4 °C. Subsequently, ganglia were immersed
for 14 h in phosphate-buffered saline (PBS-Dulbecco) containing 18% sucrose at 4 °C. Fixed
ganglia were frozen in isopentane at −50 °C and 30 μm thick sections were cut on a cryostat
and subsequently used as free-floating sections for immunocytochemistry. For some
experiments after perfusion and immersion fixation rat ganglia were embedded in paraffin.
Paraffin sections, 7 μm thick, were used for immunocytochemical as well as for in situ
hybridization experiments.
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For extraction of total RNA and angiotensin components rats were shortly anesthetized with
ether and subsequently sacrificed by decapitation. Fresh rat trigeminal ganglia were dissected
and instantly transferred into RNA later (Ambion), frozen in liquid nitrogen, and then processed
for total RNA extraction (Ambion). For angiotensin component extraction, trigeminal ganglia
were rapidly removed, rinsed with cold Ringer solution, blotted by filter paper and wet weight
was measured. The ganglia were frozen in liquid nitrogen and stored at −70 °C.
Human trigeminal (semilunar) ganglia were procured from three adult individuals for whom
a permit for clinical autopsy (informed written consent by next of kin) had been obtained
according to state law, in accordance with the Code of Ethics of the World Medical Association
(Declaration of Helsinki). After removal of the brain with transection of the cranial nerve roots
along the brainstem and harvest of the pituitary gland from the sella, the superficial dura of the
middle cranial fossa was removed by traction with forceps. The semilunar ganglion was then
easily detached from its bed (Meckle's cave) and the three trigeminal branches transected at
their passage through the foramina. Human trigeminal ganglia were fixed by immersion in
freshly prepared 2% formaldehyde for 3 days and then used for cryosectioning or embedded
in paraffin.
2.2. RNA isolation and quantitative realtime RT-PCR (qRT-PCR)
Total 6 trigeminal ganglia from different WKY rats were taken for total RNA extraction. RNA
integrity was confirmed for each sample on the Agilent Bioanalyzer using the RNA 6000 Nano
kit (Agilent Technologies). 1 μg of total RNA was reverse transcribed using Superscript II
(Invitrogen) and random hexamers according to the manufacturer's protocol. For realtime PCR,
reverse transcribed material corresponding to 40 ng RNA was amplified with the TaqMan
assays described below in 25 μl Universal PCR Master Mix, No AmpErase UNG on the SDS
7000 (Applied Biosystems) using the standard thermal protocol. Average values and standard
deviations of relative mRNA levels of each sample, normalized to relative 18S rRNA levels,
are from four measurements and were calculated using the relative differences. The following
TaqMan assays were used for qRT-PCR at a final concentration of 250 nM TaqMan probe and
900 nM of each primer:
Angiotensinogen
Forward primer 5′-CACGACTTCCTGACTTGGATAAAGA-3′;
Reverse primer 5′-CTGCGGCAGGGTCAGA-3′;
TaqMan probe 5′-FAM CCTCGGGCCATCC GMGB- 3′;
manufactured as Assays-by-Design (RATG-EJ3) by Applied Biosystems.
Renin Assay-on-demand Rn00561847_m1 from Applied Biosystems.
ACE Assay-on-demand Rn00561094_m1 from Applied Biosystems.
Cathepsin D Assay-on-demand Rn00592528_m1 from Applied Biosystems.
18S rRNA Predeveloped Assay Reagent 431-9413E from Applied Biosystems.
2.3. In situ hybridization
2.3.1. DIG-labelled RNA probe preparation—By using an appropriate cDNA template
for Ang-N [31], a 403 bp long fragment corresponding to nucleotides 221–623 was generated
by digestion with restriction enzymes EcoRV and Bam HI. The obtained fragment was cloned
between Stu I and Bam HI into pBluescript I KS+ (Stratagene). Digoxigenin-labelled probes
were prepared using the DIG-RNA-labelling Mix (Roche) according to the manufacturer's
protocol. T7 RNA polymerase was used to generate antisense riboprobe using the Hind III
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linearized template, and the sense strand (used as a control) was generated by T3 RNA
polymerase using the same template linearized with Bam HI (for gel images please see online
supplementary method). The RNA concentration was estimated comparing dot-blot tests and
NanoDrop measurements. Filter hybridization with RNA extracts from trigeminal ganglia
(RNaqueous-4PCR kit from Ambion) was used for binding tests.
2.3.2. Procedure for in situ hybridization—For in situ hybridization, 6 μm thick paraffin
sections were rehydrated in a graded alcohol series (2 times Xylol for 10 min, EtOH 100% (2
times), 96%, 70%, 50%, DEPC H2O each step 5 min) using DEPC-treated H2O for the dilution
of all reagents and solutions. The sections were equilibrated in proteinase K buffer (100 mM
Tris, 50 mM EDTA, pH 7.5) for 5 min and then treated with proteinase K (19 μg/ml) at 37 °
C for 2 min, after a wash with DEPC-treated H2O. Following a wash in DEPC-water, sections
were post fixed with freshly prepared 4% formaldehyde for 5 min, followed by two subsequent
washes in DEPC-water for 5 min each. Sections were then incubated in prehybridization
solution (SIGMA) at 45 °C for 2 h, followed by incubation with heat denatured sense and
antisense riboprobes (5–10 ng/μl) in 30 μl hybridization mix (SIGMA) for 48 h at 45 °C in a
humid chamber (saturated with 2× SSC). Subsequently, the sections were incubated with 2×
SSC for 30 min at room temperature, followed by 1 h in 2× SSC at 45 °C and 1 h in 0.1× SSC
at 45 °C. Sections were equilibrated for 5 min with buffer 1 (100 mM Tris, 150 mM NaCl, pH
7.5), then incubated with alkaline phosphatase-coupled anti-digoxigenin antibody (Roche)
1:500 diluted in buffer 2 (10× blocking solution diluted with buffer 1) for 2 h at room
temperature, followed by two 5 min washes with buffer 1. Finally, after 5 min equilibration
with buffer 3 (100 mM Tris, 100 mM NaCl, 50 mM MgCl2, pH 9.5), the color reaction
containing NBT and BCIP in buffer 3 was completed according to manufacturer's protocol
(Sigma).
2.4. Immunocytochemistry
For immunocytochemical incubations, a protein G purified murine monoclonal antibody
against Ang II (Mab-Trap G II column, Amersham Sciences) was used at a concentration of
0.3 μg/ml in buffer solution. This is a self generated monoclonal antibody against the synthetic
peptide to human Ang II. The specificity for the monoclonal antibody against Ang II (4B3)
has been previously documented and it produced the same staining as a polyclonal antibody
against Ang II in rat adrenal glands [20]. For immunization of the mice, Ang II peptide was
cross-linked with glutaraldehyde to keyhole limpet hemocyanin. In dot blot assay, the
monoclonal antibody against Ang II (4B3) showed total cross reactivity with Ang III (2–8),
Ang 3–8, Ang 4–8 and Ang 5–8. It showed no cross reaction with human plasma
angiotensinogen, Ang I (1–10) and angiotensin 1–7. Pre-absorption was performed by using
a batch procedure with the synthetic Ang II-peptide that was covalently linked through its N-
terminus to CH-Sepharose 4 B. The gel was loaded into a glass column and the monoclonal
anti Ang II-antibody solution effluent was used for immunocytochemical preabsorption
controls. Further controls were done with mouse non-immune serum and for the secondary
goat anti-mouse Cy3 antibody without the primary antibody. All these additional controls
showed absolute no staining within the sections. The pre-absorbed monoclonal antibody after
low pH-elution revealed the same staining as the Mab-Trap G II purified antibody.
Substance P was detected with a mouse monoclonal antibody to the synthetic peptide Substance
P from Novus Biologicals (SP-DE4-21). Goat anti-mouse immunoglobulins (GAM Cy3;
Jackson ImmunoResearch) pre-incubated with rat serum prior to immunocytochemistry were
used as secondary antibodies. Sections were incubated free floating for 36 h at 4 °C with the
primary antibody, washed and incubated with the secondary antibody for 90 min at room
temperature and counterstained with DAPI (4′,6-diamidino-2-phenylindole). After washing,
cryosections were mounted on gelatin-coated slides and air-dried. The stained sections were
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embedded with Glycergel (DAKO) and cover-slipped. The same procedure as for free floating
cryosections has been used for paraffin sections mounted on glass slides. Pictures were taken
by a normal fluorescent light microscope (LEICA DM 6000B) using a digital camera or by a
confocal laser scanning microscope (LEICA SP2 with AOBS).
2.5. Colocalization studies
Directly adjacent free-floating cryosections of rat trigeminal ganglia were immunostained for
Ang II and Substance P, as mentioned under methods (2.4 Immunocytochemistry). Pictures
were taken by a normal fluorescent light microscope (LEICA DM 6000B) using a digital
camera LEICA-DFC350FX. The total number of neurons was counted for each adjacent
section, and nuclei which were counterstained with DAPI in blue. Ang II and Substance P
immunopositive neurons were counted in respective adjacent sections. For colocalization
studies Substance P staining was digitally changed to yellow from red, taking the advantage
of directly adjacent sections we superimposed the Ang II and Substance P sections by using
Corel Draw and colocalized neurons where counted.
2.6. Measurement of angiotensin peptides
Immunoreactive Ang II (ir-Ang II) as well as Ang-(1–8) octapeptide, Ang-(2–8) heptapeptide,
Ang-(3–8) hexapeptide, Ang-(4–8) pentapeptide, Ang-(1–10) decapeptide and Ang-(2–10)
nonapeptide were measured in rat trigeminal ganglia by radioimmunoassay without and with
prior separation by high performance liquid chromatography (HPLC) [34]. Measurement of
true angiotensin was applied also for Ang I, and peptide extraction from tissue was adapted
for additional freeze-thaw procedures to ensure the lysis of cells [35,36]. Briefly, trigeminal
ganglia weighing 14.8–21.9 mg were homogenized in 1.5 ml water, shock frozen in ethanol/
dry ice, thawed in a 37 °C water bath. The freeze-thaw procedure was repeated twice. Samples
were sonicated for 10 min at 37 °C, centrifuged at 3500 g and the supernatant in an albumin-
coated polypropylene tube was dried at 37 °C under nitrogen. The residue was dissolved in 2.2
ml Tris buffer (0.1 M, pH 7.5) containing bovine serum albumin (5 g/l). Solid-phase extraction
on phenylsilylsilica, HPLC and radioimmunoassay were performed according to the routine
procedures using very sensitive antisera for Ang II and Ang I with cross-reactivities of 53%
for Ang-(2–8) heptapeptide as well as for Ang-(3–8) hexapeptide, 52% for Ang-(4–8)
pentapeptide, and 33% for Ang-(2–10) nonapeptide, respectively [35,36]. Recoveries for the
different Ang peptides and for ir-Ang II were consistently above 67% except for the
nonapeptide (34±2%, mean±SD). Therefore, no corrections were made for recovery losses.
Results are presented as fmol Ang per gram wet weight. Detection limits were variable
according to the various weights of individual ganglia. Results below detection limits were
taken as zero. All measurable Ang concentrations were at least at 150% of the detection limit
except for one hexapeptide result at the detection limit. Instead of homogenates, controls of
1.5 ml water were extracted and quantitated with every analysis and any traces of Ang peptides
found in these “blanks” were subtracted to obtain final ganglial concentrations. In 3 rats, ir-
Ang II of one trigeminal ganglion was compared with the sum of the specifically measured
Ang peptides of the contra lateral trigeminal ganglion. Immunoreactivity of the metabolites
was calculated using the cross-reactivity as a factor.
3. Results
3.1. Quantitative real time RT-PCR
In order to demonstrate the existence of Ang II in the trigeminal ganglion we investigated the
presence of different RAS components. We detected substantial amounts of Ang-N- and ACE-
mRNA in the rat (Fig. 1a and c) trigeminal ganglion by qRT-PCR. No renin mRNA was
detected (Fig. 1b). We have discovered cathepsin D mRNA, a possible alternative pathway for
Ang I formation (Fig. 1d). RNA from tissues with previously reported high levels of the
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respective mRNAs were used as positive controls, and all mRNA values were normalized to
18S rRNA.
3.2. In situ hybridization and post in situ hybridization immunocytochemistry
With paraffin sections, Ang-N mRNA was identified in most, if not all the neurons studied in
the rat trigeminal ganglion (Fig. 2a and b). Ang II immunoreactivity was present in both the
neuronal cytoplasm and neuronal processes in the rat trigeminal ganglion (Fig. 3). However
some neurons were not stained for Ang II (Fig. 3). Additionally we demonstrate Ang II staining
in the rat central nervous system (CNS) in the spinal trigeminal tract (Fig. 4a and b).
In the human trigeminal ganglion Ang II immunoreactivity was observed in the cytoplasm (see
movie 2, as online supplement) of many neurons and in their processes with both paraffin and
free-floating cryosections (Fig. 5a and b).
We used rat paraffin sections for post in situ hybridization immunocytochemistry to determine
the colocalization of Ang-N mRNA and Ang II in trigeminal ganglia neurons. In the rat, we
found that some, but not all the Ang-N mRNA positive neurons (Fig. 6a) were stained for Ang
II (Fig. 6b) as revealed in Fig. 6c.
3.3. Immunocytochemistry and colocalization studies
In directly adjacent free-floating cryosections of rat trigeminal ganglia, we detected a number
of Ang II (Fig. 7a) and of Substance P-positive neurons (Fig. 7b) and their respective processes.
In consecutive paraffin sections we found that out of total neurons, approximately 25% neurons
were immunopositive for Ang II (Fig. 8a) and 7 to 8% for Substance P (Fig. 8b). In sum of
Ang II and Substance P positive neurons approximately 7% neurons indicated Ang II
colocalized with Substance P. The number of Ang II neurons was higher than that of Substance
P neurons, and some Ang II positive cells did not contain Substance P (Fig. 8c).
3.4. Concentration of angiotensin peptides in trigeminal ganglia
Immunoreactive Ang II was found in 9 of 10 extracted trigeminal ganglia (76±53 fmol/g, mean
±SD, median 53 fmol/g). Ang I or Ang-(1–10) decapeptide was never (n=10) found above any
detection limit (≥4 fmol/g) and no Ang-(2–10) nonapeptide was found in a single experiment.
Ang-(1–8) octapeptide was measurable only in one of eight individual ganglia, but in 2 out of
3 pooled ganglia extracts. Only 3 of 6 ganglia contained Ang-(2–8) heptapetide (33±28 fmol/
g, median 27 fmol/g), but 5 of 6 ganglia contained Ang-(3–8) hexapeptide (32±22 fmol/g,
median 22 fmol/g). Significant amounts of Ang-(4–8) pentapeptide were present in 4 of 6
ganglia (55± 49 fmol/g, median 87 fmol/g). Table 1 presents levels of Ang I, Ang II, Ang III,
Ang IV and Ang V and corresponding detection limits measured in trigeminal ganglia extracts
pooled from 2 rats: All Ang peptides except Ang I were found well above detection limits. For
individually examined rats, the sum of true Ang II (Ang-1–8) and specifically measured
metabolites Ang III, Ang IV and Ang V of the left sided trigeminal ganglion corresponded
well with ir-Ang II extracted from the right sided trigeminal ganglion (Fig. 9).
4. Discussion
The proposal of important roles of Ang II in peripheral sympathetic and sensory ganglia [37,
38] and our clear demonstration of the intraneuronal expression of Ang II in the trigeminal
ganglia, raises the issue of the possibility of local Ang II formation in these neuronal tissues.
The existence of an endogenous angiotensinergic system in the neurons of rat and human
sympathetic coeliac ganglia has been reported recently [37]. In our current work we provide
evidence for local formation of Ang II in sensory neurons of trigeminal ganglia. First, we report
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with the use of qRT-PCR, the presence of Ang-N mRNA and ACE mRNA in the tissue extracts
of trigeminal ganglia from rats. Second, in situ hybridization confirmed the existence of Ang-
N mRNA at cellular level in the cytoplasm of rat trigeminal ganglia neurons. Ang-N mRNA
detection by in situ hybridization demonstrates that Ang-N could be locally formed in this
tissue, indicating that Ang-N uptake from the circulation is not necessary for the local formation
of Ang II. With the exception of one earlier communication on the presence of Ang-N mRNA
in the rat trigeminal ganglion extracts [7] ours is the first report on the presence of angiotensin
system components at cellular resolution in this structure.
We did not detect the expression of mRNA for renin, the enzyme classically considered
necessary for cleaving Ang-N into the Ang I precursor of angiotensin II [38], in the rat
trigeminal ganglion. Instead, we detected expression of cathepsin D mRNA in the trigeminal
ganglia, at levels higher in comparison with those found in rat liver and kidney, but lower in
comparison to those recently reported in rat coeliac ganglia [37]. Cathepsin D is a protease
capable of cleaving Ang-N into angiotensin I [48], a non-renin alternative pathway for Ang I
formation. Our results are in agreement with an earlier report of the existence of cathepsin D
enzymatic activity in rat trigeminal ganglion neurons [1]. These results indicate the existence
of an alternate pathway for Ang II synthesis in trigeminal ganglion sensory neurons.
Alternatively, neurons of trigeminal ganglion may take up circulating renin to support local
synthesis of endogenous Ang II [21]. These mechanisms have been proposed for other tissues
such as the heart, where strong evidence exists for uptake of extracellular renin from the
circulation [38,10,53,44], while the presence of renin in cardiac tissue is still a matter of
controversial debate [16,38–40,45,50,53,56].
In the brain, Ang-N is localized to multiple cell types, predominantly in astrocytes but also in
neurons [26]. The expression of the Ang-N gene in selective groups of neurons has been
conclusively demonstrated in the murine central nervous system [55]. Our in situ hybridization
studies demonstrate the presence of Ang-N mRNA specifically in most, but not all, the neuronal
cell bodies of the trigeminal ganglia, and not in surrounding cells (Fig. 6a). Not all Ang-N
mRNA containing neurons stained for the same extent for Ang II (Fig. 6c). There are several
possibilities for this result, including lack of Ang II internalization or storage in these neurons,
Ang II production in amounts too low to be detected with our immunocytochemical methods,
or to different roles for Ang-N, not related to Ang II formation [9,29].
We have detected Ang II-like immunoreactivity in the cytoplasm of neurons and their processes
(Figs. 3, 5 and 7a) within the trigeminal ganglia. Ang II immunoreactivity was found in higher
concentration in small and medium sized neurons as compared to large neurons of the rat and
human trigeminal ganglia. The use of polyclonal, affinity-purified, monospecific antibodies to
Ang II (BODE 1) [5] have revealed similar distribution of Ang II immunoreactivity within the
neurons of the rat trigeminal ganglia as with the applied monoclonal anti Ang II (4B3) antibody.
We could also detect angiotensinergic processes in the rat CNS in the spinal trigeminal tract
(sp5), indicating that Ang II may act as a neurotransmitter in the CNS (Fig. 4a and b). Hence,
we can hypothesize that locally formed Ang II may be transported to the terminal fields
innervated by the trigeminal ganglion in order to act as a neurotransmitter for sensory
transmission, a function similar to that demonstrated in the sympathetic nervous system [37].
Our results demonstrate the presence of Ang II and its metabolites in extracts of trigeminal
ganglia of Wistar–Kyoto rats (Table 1) at concentrations well comparable with other tissue
concentrations of Ang II established in Wistar rats with similar methodology [36]: These tissue
levels were depending on the organ about tenfold higher than plasma concentrations (4.4±0.4
fmol/ml), in heart (10.1±1.2 fmol/g), muscle (30.3.±3.5 fmol/g), liver (69.7±6.9 fmol/g), lung
(79.5± 9.7 fmol/g), kidney tissue (192±23 fmol/g), but low in whole brain (3.2±0.5 fmol/g)
and very high in adrenal gland (3061±159 fmol/g). The Ang II concentration in WKY rat
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trigeminal ganglia is thus six fold higher than whole brain Ang II in Wister rats. Interestingly,
brain Ang I (decapeptide) levels (3.0±0.7 fmol/g) in Wister rats were comparable to Ang II
levels, but similar concentrations in trigeminal ganglia would have been below detection limit
(<3.95 fmol/g) of the present work since maximally 121 mg pooled ganglial tissue was
available. It cannot be concluded that Ang I is absent in trigeminal ganglia, but if it would be
present it had to be fivefold below Ang II levels and less than half of all other measured Ang
peptides.
The reliability of our Ang measurements is well documented by the close relation between ir-
Ang II of one-sided ganglia extract and the sum of immunoreactivities of all specifically
measured Ang peptides of the contra lateral trigeminal ganglion. There can be little doubt that
the Ang II visualized by immunocytochemistry in trigeminal ganglia is indeed Ang II or its
metabolites. In the context of perivascular Ang II immunocytochemical stainings and visibility
of corresponding varicosities as synapses en passant, a role for angiotensin as a
neurotransmitter is very likely [37].
Additionally, we attempted to determine whether Ang II was associated with other
neuropeptides in the trigeminal ganglion. From the multiple neurotransmitters and
neuromodulators identified in this ganglion, we chose Substance P, a neuropeptide established
as a key regulator of sensory transmission in the trigeminal ganglion [17,25,30]. We found that
Ang II was colocalized with Substance P in trigeminal ganglion neurons (Fig. 8), supporting
the hypothesis of a close integration between these two systems, and the previous reports of
regulation of Substance P release by Ang II [14,28,22]. We found that in the total of 826 neurons
of trigeminal ganglia 214 were stained for Ang II, 60 were stained for Substance P, whereas
20 neurons were showing colocalization of Ang II and Substance P (Fig. 8c). Neuronal
colocalization suggests the possible interaction of Ang II with Substance P and further
involvement of Ang II in trigeminal neuralgia and nociception [12,42,43,46]. Angiotensin
receptor type 1 have been reported in the nucleus tractus solitarri (NTS) of rat brain [19,47],
moreover Substance P receptors are also localized in NTS of rat brain [32].
Our results are not without clinical interest. The trigeminal ganglion provides sensory afferents
to the cerebral blood vessels [15] and the trigeminovascular system is involved in the
pathophysiology of migraine, cerebrovascular vasospasm, chronic pain and inflammatory
syndromes [6,13,23]. RAS inhibition through ACE inhibitors or Ang II type 1 receptor
blockade appears to be effective for the prevention of migraine, independently of their blood
pressure lowering effects [8,49,51], to increase resistance to brain ischemia [27,33] and to
reduce cerebrovascular inflammation [2,57]. It is reasonable to propose that Ang II, formed in
the neurons of trigeminal ganglia, plays an important role in cerebrovascular pathophysiology
either directly and/or in association with other transmitter systems such as Substance P or
calcitonin gene-related peptide [30]. Ang II has an antinociceptive effect during high pain
sensitivity [42]. Interactions between the Substance P and RAS are also proposed in the pineal
gland, which receives Substance P innervation from the trigeminal ganglia [46] and expresses
a local RAS system [3].
In conclusion, our findings strongly indicate the presence of a local angiotensinergic system
in neurons of the trigeminal ganglia, where Ang II may act as a neurotransmitter. The roles of
Ang II in the trigeminal ganglia possibly include the regulation of sensory pathways including
pain and the functions of other local neurotransmitters.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
Determination of relative mRNA levels in rat trigeminal ganglia. Reverse transcribed total
RNA extracts of rat trigeminal ganglia from different rats were tested by qRT-PCR for the
presence of Ang-N mRNA (a), for renin mRNA (b), for ACE mRNA (c) and cathepsin D
mRNA (d). Total RNA extracts from liver (a), kidney (b), lung (c) and liver–kidney (d) were
used as a reference samples expression. All relative mRNA values are normalized to 18S rRNA
levels. Average values and standard deviations of 4 qRT-PCR measurements are shown.
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Fig. 2.
In situ hybridization in rat trigeminal ganglion for detection of Ang-N mRNA, 6 μm thick
consecutive paraffin sections were processed as described in methods. a) sense probe. b) with
antisense probe, revealing positive staining in the cytoplasm of numerous neurons within the
ganglion. Bar: 100 μm.
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Fig. 3.
Ang II immunocytochemistry in rat trigeminal ganglion. 30 μm thick free-floating cryosections
were prepared and incubated with our murine monoclonal antibody against Ang II [20], stained
with goat anti-mouse (GAMCy3) in red and DAPI in blue for nuclei, as described under
methods. Note, the intensity of the staining for Ang II varies among the neurons and their
projections, some neurons are not stained for Ang II (see arrows). Bar: 50 μm. See movie 1 in
supplementary material.
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Fig. 4.
Angiotensinergic neuronal processes within the central nervous system in the rat spinal
trigeminal tract (sp5) [41]. a. Bar: 200 μm. b. Bar: 100 μm.
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Fig. 5.
Ang II immunocytochemistry in human trigeminal ganglion. a. A 6 μm thick paraffin section,
incubated with murine monoclonal anti Ang II antibody [20], stained with goat anti-mouse
(GAMCy3) in red and DAPI in blue for nuclei. Note, Ang II staining in neuronal cytoplasm
and projections and the intensity of the staining varies among the neurons. Autofluorescence
of lipofuscin granules is shown in yellow, Bar: 50 μm. b. A free floating 30 μm thick
cryosection, incubated with murine monoclonal anti Ang II antibody stained with goat anti-
mouse (GAMCy3) in red and DAPI in blue, as described under methods. Ang II staining in
trigeminal neurons is cytoplasmic and in processes (see arrows). The picture was taken with a
confocal laser scanning microscope. Bar: 50 μm. See movie 2 in supplemented material.
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Fig. 6.
Colocalization of Ang-N mRNA and Ang II immunoreactivity in the rat trigeminal ganglion.
A 7 μm thick paraffin section was processed for in situ hybridization with the antisense probe
to detect Ang-N mRNA (a) followed by immunocytochemistry for Ang II as described in
methods (b) post in situ hybridization immunocytochemistry (c) Here angiotensinergic staining
in neurons and projections is in greenish-blue color. Note that not all Ang-N mRNA-expressing
neurons stain for Ang II to the same extent. Bar: 100 μm.
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Fig. 7.
Ang II and Substance P immunocytochemistry in rat trigeminal ganglion. Directly adjacent,
30 μm free-floating cryosections were incubated with Ang II (a) or Substance P (b) antibodies
and stained with goat anti-mouse (GAMCy3) as secondary antibodies in red and DAPI in blue
as nuclear stain, as described under methods. Bar: 200 μm.
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Fig. 8.
Colocalization of Ang II and Substance P (SP) immunoreactivity in rat trigeminal ganglion
neurons. Directly adjacent, 6 μm thick paraffin sections were incubated with Ang II (a) or
Substance P (b) antibodies and then stained with goat anti-mouse (GAMCy3) as secondary
antibodies in red, DAPI for nuclei in blue. In order to perform the colocalization studies
Substance P originally stained in red, was digitally changed to yellow. Arrows indicate
colocalized, positive neuronal staining Bar: 50 μm. Note that more neurons were stained for
Ang II than for Substance P, while some neurons show colocalization of Ang II with Substance
P. Statistical analysis showing total neurons of trigeminal ganglia sections, Ang II-, Substance
P-positive neurons and their colocalization (c).
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Fig. 9.
Concentration of ir-Ang II (RIA) and specifically measured Ang peptides (HPLC-RIA) in
trigeminal ganglia of 3 rats: The sum of individually measured Ang peptides of one trigeminal
ganglion parallels levels of ir-Ang II as measured in the contralateral trigeminal ganglion.
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